Opioid agonists, mixed agonist-antagonists and partial agonists

34,242views

test

00:00 / 00:00

Opioid agonists, mixed agonist-antagonists and partial agonists

Med int

Med int

Antihistamines for allergies
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Infective endocarditis: Clinical
Valvular heart disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympathomimetics: Direct agonists
Muscarinic antagonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Loop diuretics
Antiplatelet medications
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
Skin and soft tissue infections: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Potassium sparing diuretics
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Cystic fibrosis: Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
Adrenal insufficiency: Clinical

Assessments

Flashcards

0 / 39 complete

USMLE® Step 1 questions

0 / 5 complete

USMLE® Step 2 questions

0 / 8 complete

Flashcards

Opioid agonists, mixed agonist-antagonists and partial agonists

0 of 39 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

USMLE® Step 2 style questions USMLE

0 of 8 complete

A 44-year-old woman presents to the emergency department following a first-time seizure. The patient was recently seen in the emergency department for symptomatic nephrolithiasis and was discharged with pain medications and urology follow-up. Her roommate, who is at the bedside, does not recall which medication she was prescribed. Past medical history includes depression, chronic pain, anxiety, and hypertension. Her current medications include sertraline, venlafaxine, amlodipine, and alprazolam. Temperature is 37.3°C (99.2°F), pulse is 111/min, respirations are 22/min, and blood pressure is 163/105 mmHg. Physical examination reveals a confused postictal individual with diaphoresis and mydriasis. Clonus and hyperreflexia are elicited in the lower extremities bilaterally. Which of the following medications is most likely responsible for this patient’s clinical findings?  

External References

First Aid

2024

2023

2022

2021

Acetylcholine (ACh)

opioid analgesics p. 567

Acute pulmonary edema

opiod analgesics p. 567

Adverse effects/events

opioid analgesics p. 567

Calcium channels

opioid effect on p. 567

Diarrhea

opioids for p. 567

opioid withdrawal p. 588

5-HT

opioid effects p. 567

Glutamate

opioid effects p. 567

Heroin

opioids for withdrawal p. 567

Miosis

opioids p. 568

Naloxone

for opioid toxicity p. 247, 567, 588

Naltrexone

opioid toxicity p. 567, 588

Norepinephrine (NE)

opioid effect on p. 567

Opioids p. 568

Beers criteria p. 246

intoxication and withdrawal p. 588

pentazocine and p. 568

sleep apnea p. 697

toxicity treatment p. 247

Potassium channels

opioid effect p. 567

Pregnancy p. 651

opiate use during p. 633

Pulmonary edema

opioids for p. 567

Respiratory depression

opioids p. 568

Vomiting

with opioid analgesics p. 567

Transcript

Watch video only

Opioid agonists are medications used mainly to control acute or chronic pain in particular situations.

Some of them are also used to treat diarrhea and cough. When treating pain, the goal should be to use short-acting opioids at the lowest effective dose for just a few days, and slowly increase their dose only as needed.

As a class, opioids share one thing in common, they bind to opioid receptors in the brain, spinal cord, and gastrointestinal tract.

Some are endogenous, meaning they are produced naturally by the body, like endorphins, short for endogenous morphine.

But others are exogenous, meaning they come from outside the body, like heroin and morphine, which come from the opium poppy; a flowering plant that oozes a milky white liquid.

To understand how opioids work, let’s zoom into a region of the brain tissue that has opioid receptors.

Normally, in the absence of endorphins, inhibitory neurons secrete a neurotransmitter called gamma-aminobutyric acid, or GABA, that prevents nearby neurons from releasing neurotransmitters like dopamine, serotonin, and norepinephrine.

Now, let’s say someone goes to play a rigorous game of badminton. Exercise releases endorphins which activate the three major opioid receptors located on the inhibitory neurons, called the mu, kappa, and delta receptors.

As endorphins bind to these receptors, they block the inhibitory neuron from releasing GABA, allowing the dopamine, serotonin, and norepinephrine secreting neurons to freely unload their neurotransmitters, which then get picked up by another neuron in the same area.

Norepinephrine and serotonin release takes place in pain processing regions of the brain like the thalamus, brainstem, and spinal cord, resulting in a decreased sensitivity to pain.

When dopamine release takes place in reward pathway regions like the ventral tegmental area, nucleus accumbens, and prefrontal cortex, the result is a calming sensation that feels really good.

Okay, so even though all opioids bind to opioid receptors, not all of them have the same effect.

Some opioids, like morphine, act just like endorphins, and when they bind to the opioid receptors, they trigger a full response that results in the complete inhibition of GABA release.

These are called full agonists. Others, like tramadol, have a weaker effect since they only partially inhibit GABA release.

These opioids are called partial agonists.

Now, some opioids act preferably on mu receptors, others on kappa or delta receptors.

In fact, they can have an agonist effect on one receptor, and an antagonist effect on others.

These are called mixed agonist-antagonists.

First, let’s look at some full agonists.

Commonly used medications in this class include morphine, methadone, fentanyl, meperidine, codeine, hydrocodone, and oxycodone.

Although not a medication, heroin is also a full agonist.

Since opioids are the strongest analgesics available, they can typically be given perorally, intravenously, or through patches in the case of fentanyl, to control severe pain that couldn’t be eased with non-opioid medications.

Fentanyl is the most potent full agonist and it’s also used as an anesthetic medication due to its rapid onset and short duration of action.

Meperidine can be used to relax uterine muscles and inhibit contractions during labor. However, it can produce respiratory depression in the baby.

Codeine is a weaker full agonist and is often taken perorally with other analgesics like acetaminophen, to treat moderate pain like headaches.

Due to an unknown mechanism, codeine and hydrocodone are also useful as an antitussive, to relieve cough in adults.

Unfortunately opioids have a high risk of causing opioid dependence.

Since they cause a wonderful euphoric feeling, there’s an increased risk of abuse and addiction.

Methadone is an opioid that does not cause euphoria and it has a long half-life, so it’s often given to decrease withdrawal symptoms for people with opioid use disorder or heroin addiction.

An added benefit is that it also blocks the euphoric feeling that comes from taking other opioids, so it helps to prevent future abuse.

There are also some opioids that don’t have any analgesic effects. For example, dextromethorphan is only used for its antitussive properties.

Loperamide can’t cross the blood brain barrier so it’s used to reduce the motility of the gastrointestinal tract and treat diarrhea.

Now, common partial agonists include buprenorphine, butorphanol, pentazocine, and tramadol.

The first three are mixed agonist-antagonists. Buprenorphine is a partial agonist at the mu receptor, but an antagonist at the kappa receptor, while butorphanol is a partial agonist at the kappa receptor, but an antagonist at the mu receptor.

Pentazocine is a partial agonist at the mu receptor and kappa receptor. All three can be used to manage moderate pain.

Tramadol is a partial agonist at the mu receptor and is used for moderate to severe pain, often after surgery.

Now if these medications are given with a full agonist, they’ll compete for the same receptors and decrease the overall effect.

Now, this can also be a good thing; as a partial agonist, buprenorphine can stimulate opioid receptors enough to decrease cravings and withdrawal symptoms in people with opioid use disorder.

However, it’s not potent enough to cause an overdose or trigger the euphoric feeling, which makes it a safer alternative to methadone.

Okay, let’s move on to side effects. In the central nervous system, excessive stimulation of opioid receptors can cause euphoria, but sometimes also dysphoria where the person feels unhappy and dissatisfied.

Summary

Opioid full agonists are drugs that bind to and activate opioid receptors in the body. They are used to treat pain and can also produce feelings of euphoria, which has led to their abuse and addiction potential. Examples of opioid agonists include morphine, codeine, and oxycodone.

Mixed agonist-antagonists bind to and activate opioid receptors to a certain extent, but also have the ability to block or inhibit the effects of other opioids. They can also be used to treat pain and may have a lower risk of abuse and addiction compared to full agonists.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment" Journal of Pharmacology and Experimental Therapeutics (2019)
  4. "Opioid Use Disorder: Medical Treatment Options" Am Fam Physician (2019)
  5. "Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?" Can Fam Physician (2017)
  6. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)